JP5020086B2 - 治療後の全身炎症性マーカーの達成レベルの関連性 - Google Patents
治療後の全身炎症性マーカーの達成レベルの関連性 Download PDFInfo
- Publication number
- JP5020086B2 JP5020086B2 JP2007535877A JP2007535877A JP5020086B2 JP 5020086 B2 JP5020086 B2 JP 5020086B2 JP 2007535877 A JP2007535877 A JP 2007535877A JP 2007535877 A JP2007535877 A JP 2007535877A JP 5020086 B2 JP5020086 B2 JP 5020086B2
- Authority
- JP
- Japan
- Prior art keywords
- level
- treatment
- marker
- human subject
- ldlc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Kentら、Am J Cardiol 2003;92:1227―1230
本発明は、全身性炎症マーカーを測定して、ヒト被験体の治療成績を改善する治療法を誘導することに関する。本発明の驚くべき局面において、治療中の全身性炎症マーカーのレベルが将来の心血管事象のリスクの予測値を有することが発見されている。全身性炎症マーカーの治療中レベルは、先行技術の予測因子の追加となるものである。このことは図2及び図3に図示されており、これらの図において本発明のデータは、LDLCレベル及びCRPレベルを考慮に入れた、ヒト被験体の有害な心血管事象の再発率を示す。図2には、LDLC又はCRPのいずれかの治療レベルに関連した心血管事象の再発率を示し、図3には、LDLCレベル及びCRPレベルの両方に関連した心血管事象の再発率を示す。前記のLDLCレベル及びCRPレベルの両方に関連した心血管事象の再発率が追加的なものであることは明々白々である。
スタチン療法は、血漿コレステロールを低下させることによって心血管事象のリスクを低減し、周知の心血管疾患を有する患者のための実施ガイドラインは、LDLCの標的目標に達することの重要性を強調している(1)。しかし、本発明者等は、炎症バイオマーカーCRPのレベルが高い場合にスタチン療法がより大きな臨床的利益をもたらし(2、3)、スタチンがLDLCに殆ど依存しない方法でCRPレベルを低下させる(3〜6)ことを証明した。これらの所見並びに基本的な実験証拠により、スタチンは強力な脂質低下剤であることに加えて、予後及び治療に重要な抗炎症特性も有する可能性があることを仮定するに至った。その場合、スタチンによる処置後の達成CRPレベルは、達成LDLCレベルと同様の臨床的関連性を有する可能性がある。
Pravastatin or Atorvastatin Evaluation and Infection Therapy − Thrombolysis in Myocardial Infarction 22(PROVE IT − TIMI 22)試験から試験集団を抽出し、2000年11月から2004年2月の間に無作為化試験を実施した。当該試験では、2×2要因計画を使用して、中程度の(プラバスタチン40mg/日、経口)スタチン療法に対する強力な(アトロバスタチン80mg/日、経口)スタチン療法の効果と、急性冠不全症候群発症後の再発冠動脈事象の予防におけるプラセボに対するガチフロキサシンの効果を評価した(7)。合計では、試験前10日までに急性冠不全症候群により入院し、書面によるインフォームド・コンセントを得た4,162人の患者が、8ヶ国349施設で登録された。その内の約2/3が急性心筋梗塞に罹患し、残りがリスクの高い不安定狭心症を罹患していた。臨床試験の組み入れ基準及び除外基準の説明は、以前に提示している(8)。
試験組み入れ時の参加者3,745人の平均年齢は58歳であり、22パーセントが女性であった。49パーセントが高血圧症の病歴を有し、17パーセントが糖尿病で、36パーセントが現役喫煙者であった。
これらのデータは、スタチン療法で処置された急性冠不全症候群患者の間において、2.0mg/L未満の目標CRPレベルの達成が、事象を発症しない生存の有意な向上と関連性があり、この効果は、達成LDLCの全レベルでみられることを示している。これらのデータは又、個々の患者のLDLC低下とCRP低下の間の関係は、用いる脂質低下療法の強度にかかわらず極めて変動が大きいことも示しており、この所見は、急性虚血を伴わない個人を対象とした以前の試験とも一致している(3〜6)。本発明者等のデータでは、達成CRPにおける3パーセント未満の変動が、達成LDLCの変動により説明されている。従って、これらのデータでは、スタチン療法により心血管リスクを積極的に低減する戦略において、コレステロールレベルと共に炎症レベルを監視することが必要になり得ることが示唆されている。
要約すると、これらの二次予防データは、スタチン療法後にLDLC及びCRPのいずれも高い目標レベルを達成した患者において、心血管事象を発症しない生存の可能性が向上したことを示している。又、これらのデータは、急性冠動脈虚血発症後の炎症を低下させる治療法が患者の転帰の改善をもたらすという仮説を裏付ける強力な証拠となっている。
Claims (20)
- ヒト被験体の診断を補助する方法であって、該方法は、以下:
(i)将来の心血管事象のリスクを低減するために、スタチンを用いた治療を受けているヒト被験体由来のサンプルの全身性炎症マーカーのレベルを測定する工程であって、ここで該マーカーは、C反応性タンパク質(CRP)、可溶性細胞間接着分子(sICAM−1)、ICAM3、BL−CAM、LFA−2、VCAM−1、NCAM、PECAM、フィブリノーゲン、血清アミロイドA(SAA)、リポタンパク質関連ホスホリパーゼA2(LpPlA2)、sCD40リガンド、ミエロペルオキシダーゼ、インターロイキン−6(IL−6)及びインターロイキン−8(IL−8)からなる群より選択される、工程、
(ii)該サンプルにおける低密度リポタンパク質コレステロール(LDLC)のレベルを測定する工程、
(iii)(i)で取得した該マーカーのレベルを、明らかに健康な対照集団における該マーカーのレベルに対応する所定の値と比較する工程、ならびに
(iv)(i)で測定した該マーカーのレベルが所定のレベルを超えるか否かを判定する工程、
を包含し、
(i)において得られた該マーカーのレベルの該判定が該所定のレベルを超えないこと、および該LDLCのレベルが70mg/dL未満であることは、該被験体が該スタチンを用いた治療の継続から利益が得られることの指標であり、(i)で得られた該マーカーのレベルの少なくとも1つのが該所定のレベルより高いこと、およびLDLCが70mg/dL未満でないことは、該被験体が該スタチンを用いた治療の変更から利益が得られることの指標である、方法。 - 前記ヒト被験体の前記マーカー及びLDLCのレベルを経時的に監視するために、工程(i)および工程(ii)が繰り返される、請求項1に記載の方法。
- 前記ヒト被験体が少なくとも1ヶ月間前記治療を受けている、請求項1に記載の方法。
- 前記ヒト被験体が少なくとも2ヶ月間前記治療を受けている、請求項1に記載の方法。
- 前記ヒト被験体が少なくとも1ヶ月間前記治療を受けている、請求項2に記載の方法。
- 前記ヒト被験体が少なくとも2ヶ月間前記治療を受けている、請求項2に記載の方法。
- 前記全身性炎症マーカーがCRPである、請求項1〜6に記載の方法。
- 前記所定の値が2mg/L又はそれ未満である、請求項7に記載の方法。
- 前記所定の値が1.75mg/L又はそれ未満である、請求項7に記載の方法。
- 前記所定の値が1mg/L又はそれ未満である、請求項7に記載の方法。
- 将来の心血管事象のリスクを低減する治療の有効性を評価する方法であって、該方法は、以下:
(i)将来の心血管事象のリスクを低減するために、スタチンを用いた治療を受けているヒト被験体由来のサンプルの全身性炎症マーカーのレベルを測定する工程であって、ここで該マーカーは、C反応性タンパク質(CRP)、可溶性細胞間接着分子(sICAM−1)、ICAM3、BL−CAM、LFA−2、VCAM−1、NCAM、PECAM、フィブリノーゲン、血清アミロイドA(SAA)、リポタンパク質関連ホスホリパーゼA2(LpPlA2)、sCD40リガンド、ミエロペルオキシダーゼ、インターロイキン−6(IL−6)及びインターロイキン−8(IL−8)からなる群より選択される、工程、
(ii)該サンプルのLDLCレベルを測定する工程、
(iii)(i)で測定した該マーカーのレベルを、明らかに健康な対照集団のマーカーのレベルに対応する所定の値と比較する工程、ならびに
(iv)(i)で測定した該マーカーのレベルが所定のレベルを超えるか否かを判定する工程、
を包含し、
(i)において得られた該マーカーのレベルの該判定が該所定のレベルを超えないこと、および該LDLCのレベルが70mg/dL未満であることは、治療が有効であることの指標であり、(i)で得られた該マーカーのレベルの少なくとも1つのが該所定のレベルより高いこと、およびLDLCが70mg/dL未満でないことは、該治療が有効でないことの指標である、方法。 - 前記ヒト被験体の前記全身性炎症マーカー及びLDLCのレベルを経時的に監視するために、工程(i)及び工程(ii)が繰り返される、請求項11に記載の方法。
- 前記ヒト被験体が少なくとも1ヶ月間前記治療を受けている、請求項11に記載の方法。
- 前記ヒト被験体が少なくとも2ヶ月間前記治療を受けている、請求項11に記載の方法。
- 前記ヒト被験体が少なくとも1ヶ月間前記治療を受けている、請求項12に記載の方法。
- 前記ヒト被験体が少なくとも2ヶ月間前記治療を受けている、請求項12に記載の方法。
- 前記全身性炎症マーカーがCRPである、請求項11〜16に記載の方法。
- 前記所定の値が2mg/L又はそれ未満である、請求項17に記載の方法。
- 前記所定の値が1.75mg/L又はそれ未満である、請求項17に記載の方法。
- 前記所定の値が1mg/L又はそれ未満である、請求項17に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61646704P | 2004-10-06 | 2004-10-06 | |
US60/616,467 | 2004-10-06 | ||
PCT/US2005/036347 WO2006042192A2 (en) | 2004-10-06 | 2005-10-06 | Relevance of achieved levels of markers of systemic inflammation following treatment |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008516243A JP2008516243A (ja) | 2008-05-15 |
JP2008516243A5 JP2008516243A5 (ja) | 2008-11-20 |
JP5020086B2 true JP5020086B2 (ja) | 2012-09-05 |
Family
ID=36148975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007535877A Active JP5020086B2 (ja) | 2004-10-06 | 2005-10-06 | 治療後の全身炎症性マーカーの達成レベルの関連性 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9164104B2 (ja) |
EP (3) | EP1809759B1 (ja) |
JP (1) | JP5020086B2 (ja) |
AU (1) | AU2005294165B2 (ja) |
CA (1) | CA2624601C (ja) |
DK (1) | DK1809759T3 (ja) |
ES (1) | ES2439229T3 (ja) |
WO (1) | WO2006042192A2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441747B2 (en) * | 2002-01-22 | 2019-10-15 | Mercator Medsystems, Inc. | Methods and systems for inhibiting vascular inflammation |
EP1809759B1 (en) * | 2004-10-06 | 2013-09-11 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
WO2009061734A1 (en) * | 2007-11-05 | 2009-05-14 | The Government Of The United States Of America As Represented By The Secretary Of The Deparment Of Health And Human Services | Identification of subjects likely to benefit from statin therapy |
US20100017182A1 (en) * | 2008-07-15 | 2010-01-21 | Szilard Voros | Method for coronary artery disease risk assessment |
CA2794097C (en) | 2010-03-23 | 2016-08-09 | Rock Creek Pharmaceuticals, Inc. | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
DK3011059T3 (da) | 2013-06-20 | 2019-05-13 | Immunexpress Pty Ltd | Biomarkør-identifikation |
WO2015070041A1 (en) * | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
CA2930925A1 (en) | 2014-02-06 | 2015-08-13 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits therefor |
WO2018057788A1 (en) | 2016-09-22 | 2018-03-29 | Mercator Medsystems, Inc. | Treatment of restenosis using temsirolimus |
WO2018218182A1 (en) | 2017-05-26 | 2018-11-29 | Mercator Medsystems, Inc. | Combination therapy for treatment of restenosis |
CN112040953A (zh) * | 2018-03-09 | 2020-12-04 | 布赖汉姆妇女医院 | 用于心血管疾病的组合治疗 |
CN212631328U (zh) | 2018-03-14 | 2021-03-02 | 墨卡托医疗系统公司 | 用于局部药物递送的医疗器械 |
WO2019246632A1 (en) * | 2018-06-22 | 2019-12-26 | The Regents Of The University Of Colorado A Body Corporate | Use of cannabinoids to increase the lipid order of cell membranes |
EP4178565A2 (en) * | 2020-07-07 | 2023-05-17 | The General Hospital Corporation | Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US149709A (en) | 1874-04-14 | Improvement in fog-alarms | ||
US4906A (en) | 1846-12-23 | Improvement in machines for carving | ||
US1807175A (en) | 1924-06-30 | 1931-05-26 | William H Russell | Coin actuated change mechanism |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4105776A (en) | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
US4316906A (en) | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4508729A (en) | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
ZA817261B (en) | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
US4337201A (en) | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4410520A (en) | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
GB2128984B (en) | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US4780401A (en) | 1984-04-09 | 1988-10-25 | Ciba-Geigy Corporation | Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications |
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
US4940727A (en) | 1986-06-23 | 1990-07-10 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US5116870A (en) | 1986-06-23 | 1992-05-26 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4772684A (en) | 1987-01-20 | 1988-09-20 | Triton Biosciences, Inc. | Peptides affecting blood pressure regulation |
US5017716A (en) | 1987-05-22 | 1991-05-21 | E.R. Squibb & Sons, Inc. | Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method |
US5091378A (en) | 1987-05-22 | 1992-02-25 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method |
US4904646A (en) | 1987-05-22 | 1990-02-27 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-COA reductase inhibitors |
US4906624A (en) | 1987-09-08 | 1990-03-06 | Warner-Lambert Company | 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US4997837A (en) | 1987-09-08 | 1991-03-05 | Warner-Lambert Company | 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US4929620A (en) | 1987-12-10 | 1990-05-29 | Warner-Lambert Company | 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis |
US4994494A (en) | 1987-12-21 | 1991-02-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | HMG-COA reductase inhibitors |
US4900754A (en) | 1987-12-21 | 1990-02-13 | Rorer Pharmaceutical Corp. | HMG-COA reductase inhibitors |
US5001144A (en) | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
US5001128A (en) | 1987-12-21 | 1991-03-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | HMG-COA reductase inhibitors |
US4939143A (en) | 1987-12-21 | 1990-07-03 | Rorer Pharmaceutical Corporation | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
US5081127A (en) | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
US4946864A (en) | 1988-02-01 | 1990-08-07 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5021453A (en) | 1988-03-02 | 1991-06-04 | Merck & Co., Inc. | 3-keto HMG-CoA reductase inhibitors |
EP0331250B1 (en) | 1988-03-02 | 1994-04-13 | Merck & Co. Inc. | Antihypercholesterolemic agents |
US4920109A (en) | 1988-04-18 | 1990-04-24 | Merck & Co., Inc. | Antifungal compositions and method of controlling mycotic infections |
US5166171A (en) | 1988-05-13 | 1992-11-24 | Hoechst Aktiengesellschaft | 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acid derivatives, salts and esters, and in treating hypercholesterolemia |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
US4897402A (en) | 1988-06-29 | 1990-01-30 | Merck & Co., Inc. | 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors |
US4963538A (en) | 1988-06-29 | 1990-10-16 | Merck & Co., Inc. | 5-oxygenated HMG-CoA reductase inhibitors |
IT1226726B (it) | 1988-07-29 | 1991-02-05 | Zambon Spa | Composti attivi come inibitori della biosintesi del colesterolo. |
US5196440A (en) | 1988-07-29 | 1993-03-23 | Zambon Group S.P.A. | Compounds active as inhibitors of the cholesterol biosynthesis |
US5180717A (en) | 1988-08-16 | 1993-01-19 | The Upjohn Company | Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol |
DE3832570A1 (de) | 1988-09-24 | 1990-03-29 | Hoechst Ag | 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US4950675A (en) | 1988-12-21 | 1990-08-21 | Warner-Lambert Company | Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis |
US4957940A (en) | 1988-12-21 | 1990-09-18 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
US4906657A (en) | 1988-12-21 | 1990-03-06 | Warner-Lambert Company | Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US4923861A (en) | 1989-02-07 | 1990-05-08 | Warner-Lambert Company | 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
US5130306A (en) | 1989-03-13 | 1992-07-14 | Merck & Co., Inc. | 5-Oxygenated HMG-COA reductase inhibitors |
US5132312A (en) | 1989-03-27 | 1992-07-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors |
DE4004820A1 (de) | 1989-08-05 | 1991-04-25 | Bayer Ag | Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
US4970231A (en) | 1989-06-09 | 1990-11-13 | Merck & Co., Inc. | 4-substituted HMG-CoA reductase inhibitors |
US5102911A (en) | 1989-06-09 | 1992-04-07 | Merck & Co, Inc. | 4-Substituted HMG-CoA reductase inhibitors |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US4992429A (en) | 1989-08-24 | 1991-02-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Novel HMG-COA reductase inhibitors |
US5098931A (en) | 1989-08-31 | 1992-03-24 | Merck & Co., Inc. | 7-substituted HMG-CoA reductase inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US4946860A (en) | 1989-11-03 | 1990-08-07 | Rorer Pharmaceutical Corporation | Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
IT1237793B (it) | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
US5025000A (en) | 1990-03-02 | 1991-06-18 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitor compounds |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5149709A (en) | 1990-07-03 | 1992-09-22 | Schering Corporation | Inhibitors of acyl-coenzyme A: cholesterol acyl transferase |
US5085992A (en) | 1990-07-19 | 1992-02-04 | Merck & Co., Inc. | Microbial transformation process for antihypertensive products |
US5112857A (en) | 1990-09-04 | 1992-05-12 | Merck & Co., Inc. | Hmg-coa reductase inhibitor metabolites |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
US5087634A (en) | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
US5182298A (en) | 1991-03-18 | 1993-01-26 | Merck & Co., Inc. | Cholesterol lowering agents |
US5256689A (en) | 1991-05-10 | 1993-10-26 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5135935A (en) | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
US5238935A (en) | 1991-05-20 | 1993-08-24 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase |
US5124337A (en) | 1991-05-20 | 1992-06-23 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase |
US5250435A (en) | 1991-06-04 | 1993-10-05 | Merck & Co., Inc. | Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I) |
US5202327A (en) | 1991-07-10 | 1993-04-13 | E. R. Squibb & Sons, Inc. | Phosphorus-containing hmg-coa reductase inhibitors |
HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
US5260332A (en) | 1992-02-07 | 1993-11-09 | Merci & Co., Inc. | Cholesterol lowering compounds |
US5262435A (en) | 1992-02-10 | 1993-11-16 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5286895A (en) | 1992-02-19 | 1994-02-15 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5302604A (en) | 1992-03-09 | 1994-04-12 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
US5369125A (en) | 1992-07-17 | 1994-11-29 | Merck & Co., Inc. | Cholesterol-lowering agents |
US5283256A (en) | 1992-07-22 | 1994-02-01 | Merck & Co., Inc. | Cholesterol-lowering agents |
US5321031A (en) | 1992-09-23 | 1994-06-14 | Schering Corporation | 1,2-disubstituted ethyl amides as inhibitors of ACAT |
US5317031A (en) | 1992-10-19 | 1994-05-31 | Merck & Co., Inc. | Cholesterol lowering compounds |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5543297A (en) | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
GB9602877D0 (en) | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
KR0125129B1 (ko) | 1993-10-08 | 1997-11-28 | 김은영 | 신규 아실-코에이 : 콜레스테롤 아실전이효소(acat) 활성 저해물질 및 이의 제조 방법 |
CN1143365A (zh) | 1994-01-10 | 1997-02-19 | 麦克弗罗斯特(加拿大)有限公司 | 作为cox-2抑制剂的苯基杂环类化合物 |
US5576335A (en) | 1994-02-01 | 1996-11-19 | Nisshin Flour Milling Co., Ltd. | Urea derivatives and their use as ACAT inhibitors |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
JP3720395B2 (ja) | 1994-09-20 | 2005-11-24 | 京都薬品工業株式会社 | 新規ヘテロ環誘導体、その製造方法およびその医薬用途 |
JPH10507765A (ja) | 1994-10-27 | 1998-07-28 | メルク フロスト カナダ インコーポレーテツド | シクロオキシゲナーゼ−2阻害剤として有用なスチルベン誘導体 |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5691374A (en) | 1995-05-18 | 1997-11-25 | Merck Frosst Canada Inc. | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5643933A (en) | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
CA2185737A1 (en) | 1995-09-18 | 1997-03-19 | Akira Yoshida | Amid and urea derivatives |
KR100388345B1 (ko) | 1995-10-05 | 2004-03-30 | 교토 야쿠힝 고교 가부시키가이샤 | 신규헤테로시클릭유도체및이것의의약용도 |
US5789413A (en) | 1996-02-01 | 1998-08-04 | Merck Frosst Canada, Inc. | Alkylated styrenes as prodrugs to COX-2 inhibitors |
US5733909A (en) | 1996-02-01 | 1998-03-31 | Merck Frosst Canada, Inc. | Diphenyl stilbenes as prodrugs to COX-2 inhibitors |
GB9607503D0 (en) | 1996-04-11 | 1996-06-12 | Merck Frosst Canada Inc | Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors |
US5922742A (en) | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
JP4191269B2 (ja) | 1996-05-17 | 2008-12-03 | 興和株式会社 | 新規なアニリド化合物及びこれを含有する医薬 |
US5677318A (en) | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
AU7100898A (en) | 1997-04-02 | 1998-10-22 | Brigham And Women's Hospital | Means of ascertaining an individual's risk profile for atherosclerotic disease |
US7030152B1 (en) * | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
JP2001520992A (ja) | 1997-10-28 | 2001-11-06 | コリア インスティテュート オブ サイエンス アンド テクノロジー | アシルcoa−コレステロール−o−アシルトランスフェラーゼ抑制剤、動脈壁上でのマクロファージ−脂質複合体蓄積の抑制剤および肝疾患予防または治療剤としてのナリンジンおよびナリンゲニン |
AU3285499A (en) | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
MXPA01006471A (es) | 1998-12-23 | 2004-03-10 | Searle Llc | Combinaciones de inhibidores de transporte de acido biliar ileal e inhibidores de proteina de transferencia de ester colesterilio cpara indicaciones cardiovasculares. |
DK1140186T3 (da) | 1998-12-23 | 2003-09-29 | Searle Llc | Kombinationer af cholesterylestertransferproteinhæmmere og derivater af fibrinsyre til hjertekar indikationer |
US6448295B1 (en) | 1999-09-23 | 2002-09-10 | G.D. Searle & Co. | Use of substituted N-fused-phenyl-N-benzyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity |
US6677341B2 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
US6677382B1 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | Substituted N,N-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
US6482862B1 (en) | 1999-12-20 | 2002-11-19 | G.D. Searle & Co. | Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity |
US6727277B1 (en) | 2002-11-12 | 2004-04-27 | Kansas State University Research Foundation | Compounds affecting cholesterol absorption |
EP1809759B1 (en) * | 2004-10-06 | 2013-09-11 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
-
2005
- 2005-10-06 EP EP05803871.2A patent/EP1809759B1/en active Active
- 2005-10-06 EP EP11151906A patent/EP2343553A1/en not_active Withdrawn
- 2005-10-06 US US11/244,716 patent/US9164104B2/en active Active
- 2005-10-06 ES ES05803871.2T patent/ES2439229T3/es active Active
- 2005-10-06 EP EP14196959.2A patent/EP2927693A1/en not_active Withdrawn
- 2005-10-06 JP JP2007535877A patent/JP5020086B2/ja active Active
- 2005-10-06 WO PCT/US2005/036347 patent/WO2006042192A2/en active Application Filing
- 2005-10-06 CA CA2624601A patent/CA2624601C/en active Active
- 2005-10-06 AU AU2005294165A patent/AU2005294165B2/en active Active
- 2005-10-06 DK DK05803871.2T patent/DK1809759T3/da active
-
2015
- 2015-10-19 US US14/886,626 patent/US11435363B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008516243A (ja) | 2008-05-15 |
EP1809759B1 (en) | 2013-09-11 |
US11435363B2 (en) | 2022-09-06 |
EP1809759A4 (en) | 2008-12-17 |
US20160266146A1 (en) | 2016-09-15 |
DK1809759T3 (da) | 2014-01-06 |
EP1809759A2 (en) | 2007-07-25 |
EP2343553A1 (en) | 2011-07-13 |
WO2006042192A2 (en) | 2006-04-20 |
AU2005294165A1 (en) | 2006-04-20 |
ES2439229T3 (es) | 2014-01-22 |
WO2006042192A3 (en) | 2007-02-08 |
AU2005294165B2 (en) | 2012-02-02 |
CA2624601C (en) | 2018-07-03 |
US20060115903A1 (en) | 2006-06-01 |
US9164104B2 (en) | 2015-10-20 |
US20070292960A9 (en) | 2007-12-20 |
EP2927693A1 (en) | 2015-10-07 |
CA2624601A1 (en) | 2006-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5020086B2 (ja) | 治療後の全身炎症性マーカーの達成レベルの関連性 | |
US7964614B2 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease | |
US8846321B2 (en) | Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events | |
US7189518B2 (en) | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases | |
US20080003199A1 (en) | IL-33 in the treatment and diagnosis of diseases and disorders | |
JP2015051981A (ja) | 真性糖尿病の検出および予防のための炎症性マーカー | |
AU782386B2 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases | |
AU2002230848A1 (en) | Inflammatory markers for detection and prevention of diabetes mellitus | |
WO2003088811A2 (en) | Gelsolin as a prognostic marker of artherosclerotic diseases | |
EP1520590A1 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases | |
EP1767222A1 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases | |
AU2005225101A1 (en) | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclered diseases | |
AU2002343620A1 (en) | Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081001 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110920 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110928 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111006 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120529 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120612 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5020086 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150622 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |